prb s807 811 (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
96
Structured Review
Cell Signaling Technology Inc
prb s807 811
Prb S807 811, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 707 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+prb/Phospho-Rb+(Ser807%2F811)+XP+Rabbit+mAb/us12594421-308-38-41
Average 96 stars, based on 707 article reviews
Prb S807 811, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 707 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+prb/Phospho-Rb+(Ser807%2F811)+XP+Rabbit+mAb/us12594421-308-38-41
Average 96 stars, based on 707 article reviews
prb s807 811 - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
other:Article Title: A novel role for α-viniferin in suppressing angiogenesis by blocking the VEGFR-2/p70 S6K signaling pathway. Article Snippet: Funding information The present research was conducted by the research fund of Dankook University in 2017 Angiogenesis plays important roles in pathological conditions such as cancer and inflammation as well as normal tissue development and homeostasis.. Here, we investigated the effects and molecular mechanisms of α-viniferin, an oligostilbene isolated from Caragana sinica, on human umbilical vein endothelial cell responses in vitro and angiogenic sprouting in aortic rings ex vivo. α-viniferin treatment inhibited mitogeninduced HUVEC proliferation by retinoblastoma protein hypophosphorylation.. In addition, α-viniferin suppressed mitogen-induced HUVEC adhesion, migration, invasion, and microvessel outgrowth. Blocking Assay:Article Title: MnTE-2-PyP Suppresses Prostate Cancer Cell Growth via H 2 O 2 Production Article Snippet: Lysed proteins of each sample were separated by a BoltTM 4–12% Bis-Tri Plus gel and transferred onto nitrocellulose membranes using an iBlot Transfer Stack (Invitrogen, Carlsbad, CA, USA). .. After blocking with 5% non-reduced fat milk in TBST for 1 h, the membranes were incubated overnight at 4 °C with the following primary antibodies: PP1CB (1:500), cyclin D1 (1:10,000), phospho-cyclin D1 (Thr 286, 1:1000), pRB, Incubation:Article Title: MnTE-2-PyP Suppresses Prostate Cancer Cell Growth via H 2 O 2 Production Article Snippet: Lysed proteins of each sample were separated by a BoltTM 4–12% Bis-Tri Plus gel and transferred onto nitrocellulose membranes using an iBlot Transfer Stack (Invitrogen, Carlsbad, CA, USA). .. After blocking with 5% non-reduced fat milk in TBST for 1 h, the membranes were incubated overnight at 4 °C with the following primary antibodies: PP1CB (1:500), cyclin D1 (1:10,000), phospho-cyclin D1 (Thr 286, 1:1000), pRB, Immunodetection:Article Title: Androgen-Induced MIG6 Regulates Phosphorylation of Retinoblastoma Protein and AKT to Counteract Non-Genomic AR Signaling in Prostate Cancer Cells Article Snippet: .. The primary antibodies used for immunodetection were for MIG6 (Proteintech, 11630-1-AP), panAKT (Cell Signaling, 4685S, lot 6), AR (Biogenex, 256M), β-Actin (Abcam, ab6276, GR3324554-1), p-AKT (S473) (Cell Signaling, 4058S, lot 14), pRb (Abcam, ab6075, lot 821737), Article Title: Androgen-Induced MIG6 Regulates Phosphorylation of Retinoblastoma Protein and AKT to Counteract Non-Genomic AR Signaling in Prostate Cancer Cells. Article Snippet: .. The primary antibodies used for immunodetection were for MIG6 (Proteintech, 11630-1-AP), panAKT (Cell Signaling, 4685S, lot 6), AR (Biogenex, 256M), β-Actin (Abcam, ab6276, GR3324554-1), p-AKT (S473) (Cell Signaling, 4058S, lot 14), pRb (Abcam, ab6075, lot 821737), |
![Changes in Ki-67 and phosphorylated Rb in tumor tissue and skin. (A) Analysis of pharmacodynamic markers show marked reduction in on-treatment biopsy. Representative tumor biopsy specimens (patient 214-0143) obtained pre-treatment and on-treatment (C1D17) were stained using antibodies to phospho-retinoblastoma protein [pRb <t>(S780)],</t> total Rb, and Ki-67. (B) The box plot depicts the expression of Ki-67, total-Rb, and pRb in 27 paired tumor tissue samples, as determined by percentage of cells staining positive. Data are presented before and after treatment, regardless of palbociclib dose level or endocrine therapy partner. (C) The box plot depicts the change in the percent of cells staining positive for expression of Ki-67, total Rb, and pRb in tumor tissue samples between baseline and on-treatment for patients receiving both 100 mg and 125 mg of palbociclib. (D) The box plot depicts pRb and Ki-67 expression, as determined by the percentage of cells staining positive in 66 paired skin biopsies taken at baseline and between day 14 and 21 of the first cycle of palbociclib. Expression is shown pre-treatment and on-treatment at both dose levels of palbociclib. pRb, phosphorylated retinoblastoma protein; total-Rb, total retinoblastoma protein; Pre, pre-treatment; On-Tx, on-treatment](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_5829/pmc12995829/pmc12995829__gr2.jpg)